Interview with Behzad Mahdavi, Executive Chairman at OpenCell Technologies: Insights on Gene Therapies, Challenges and Solutions

Gene therapy offers groundbreaking possibilities for treating genetic disorders, yet its journey to mainstream clinical use is hindered by key obstacles, involving safety, efficacy, delivery, and high manufacturing costs. In this interview with Muhammad Younis, OpenCell Technologies' Executive Chairman Behzad Mahdavi shared deep insights on these pressing challenges and

From Discovery Park to Merck, Major Industry Players to Showcase at London Biotechnology Show 2025

London, November 4: Back for its second year, the London Biotechnology Show (#LBS25) gathers prominent biotech leaders, policymakers, and industry enthusiasts for an unparalleled showcase. Attendees can look forward to an impressive roster of returning sponsors and exhibitors with enhanced packages, alongside a diverse array of new participants. Discovery Park

UK Biotech Sector Achieves Impressive £808 Million in Q3 Funding

October 21, 2024: The UK biotech sector achieved an impressive £808 million in funding during Q3 2024, successfully navigating challenging global market conditions and showcasing sustained investor confidence. This information comes from the latest report by the BioIndustry Association (BIA). Venture capital funding remained strong, totaling £536 million across 18

UK’s Life Science Sector Receives £279 Million Boost to Combat Health Issues

October 14, 2024: The UK's leading life sciences sector is set to receive a £279 million boost to address major health challenges, as Lilly, the world's largest pharmaceutical company, has expressed its intent to invest in the UK. Under a new collaboration outlined in a memorandum

IMU Biosciences Joins Innovative UK Research Consortium on Cancer Immunotherapy Responses

October 07, 2024: IMU Biosciences, a biotechnology company at the forefront of systems-level immune profiling using AI to advance precision medicine, has announced its involvement in MANIFEST (Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity), a new UK-wide initiative aimed at understanding patient responses to immunotherapy and associated side